BioSpecifics Technologies Corp.  

(Public, NASDAQ:BSTC)   Watch this stock  
Find more results for Marc Guitman�
38.77
+0.82 (2.16%)
Mar 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.77 - 39.25
52 week 22.23 - 42.00
Open 37.82
Vol / Avg. 27,190.00/27,697.00
Mkt cap 255.88M
P/E 58.76
Div/yield     -
EPS 0.66
Shares 6.74M
Beta 1.03
Inst. own 57%
May 6, 2015
Q1 2015 Biospecifics Technologies Corp Earnings Release (Estimated) Add to calendar
Mar 13, 2015
Q4 2014 Biospecifics Technologies Corp Earnings Call - Webcast
Mar 13, 2015
Q4 2014 Biospecifics Technologies Corp Earnings Release
Mar 9, 2015
Biospecifics Technologies Corp at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 41.27% 33.00%
Operating margin 61.69% 49.72%
EBITD margin - 50.57%
Return on average assets 26.64% 17.12%
Return on average equity 27.36% 17.67%
Employees 5 -
CDP Score - -

Address

35 WILBUR ST
LYNBROOK, NY 11563-2358
United States - Map
+1-516-5937000 (Phone)
+1-516-5937039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. It has development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase (which Auxilium has named XIAFLEX) for marketed indications and collagenase clostridium histolyticum (CCH) for indications in development. Auxilium has an option to acquire additional indications that it may pursue, including human and canine lipoma. Auxilium is selling XIAFLEX in the United States for the treatment of Dupuytren�s contracture and Peyronie�s disease. Auxilium entered into an agreement with Swedish Orphan Biovitrum AB (Sobi) pursuant to which Sobi has marketing rights for XIAPEX (the European Union trade name for collagenase clostridium histolyticum) for Dupuytren�s contracture and Peyronie�s disease in Europe and certain Eurasian countries.

Officers and directors

Thomas L. Wegman President, Principal Executive Officer, Principal Financial Officer, Director
Age: 59
Bio & Compensation  - Reuters
Mark N. Wegman Ph.D. Director
Age: 64
Bio & Compensation  - Reuters
Toby Wegman Director
Age: 79
Bio & Compensation  - Reuters
Paul A. Gitman M.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
George M. Gould J.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Michael Schamroth Independent Director
Age: 74
Bio & Compensation  - Reuters